Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
As we await the GSK news in the morning, it is very improbable that GSK will not use it in combo with nirapari. The possibility of them handing it back looks remote. If however they don't intend to hold it I'm sure that there are other suitors out there salivatin
We read and form impressions of our fellow posters, even have an imaginary visual image of those posters that is based on the information gained. What we usuallydon't know are the particular cerumstances, including health of those posters. Notalot and Ashpot, within our community, have given us this insight and all of us are rooting for them and are with them in spirit. We are also supporters of, and investors in Sareum aCompany that may hopefully play a role in curing the terrible affliction that cancer can bring. To you Notalot, a speedy healing and sustained recovery, and to your wife Ashpot, a successful and speedy recovery.
Looks like Dilly was not idle, in relation to SRA 737 during his tenure with Sierra, to be fair. What a potentially phenomenal drug in combo and promising to be of huge benefit to the many that are suffering from many forms of terminal cancers. Well done HBD for this find and I have no doubt that the sp rise was on the basis of this find and an honourable mention to citizen for his earlier post this morning that began the tide turning. Proves, in my opinion the power of this board and the wonderful band of great researchers and positive posters who alert many to the phenomenon that is Sareum. Our time in the sun is fast approaching.
The broker note indicates a 60% under valuation to 300 + I assume that the CTA in a number of conditions and Covid, eagerly awaited, will up our valuation. As the preclinical indicates excellent toxidity findings and noting that 80% of new drugs pass P1, looks exceptionally promising it must make our possibility of licensing or TOreally strong. This must significantly enhance our share price going forward. And then we also await GSK's
news on plans for CHK1, while 1802 gets set to emerge. What sp then.
Yes Citizen, Sareum's Tyk 2x2 hot hot hot. Chk1 also hot hot hot. Could see a major Pharma TO soon or possibly buy in. They also get the Daddy SKIL platform, hot hot hot. Wouldn't be surprised if there's an auction situation developing. The price not that long ago was over 9p +(4.50 quid +). It settled at 7p (3.5 quid) for some time. No failure since then, just nearer the news that most on here expect to be really positive. Would expect our journey north to progress.
Interesting HD. This bb should appoint you head of GCHQ or more accurately in this case head of the SIA. (Sareum Intelligence Association). You have my vote. Am I right in thinking however that you are suggesting that there are offers probably being made but rejected by Sareum. Interesting that Thoth believes that a TO is in the works and he is waiting for the volune in trades to begin to reflect that.
The range of indications and applications of both Tyk2 and sra 737 (in combo) is staggering. The potential for Sareum 's TYK2's in both cancer and autoimmune is so extensive that I would have thought that every large pharmaceutical company without a Tyk2 or any a Tyk2 that can compete can hardly afford to let Sareum go to a competitors Not alone would they potentially lose out on all those potential indications but their own valuable drugs in cancer and autoimmune could in time be for the knackers yard. I believe that the value in lives and in medicine are so far reaching that it could be best bought in by a a Government agency that could look at it in the context of the future of medicine. There has to be
massive interest out there and yet it still seems under the radar.
Sierra did not have the finance to see Mono through to commercialisation, never mind to put SRA 737 into trialling. Getting GSK to do a buyout leaves SRA 737 in a fantastic position to be trialled in combo in a number of indications. It's not as if it's a new kid on the block, it's simply the best, the one and only left in its class left standing with a good tox profile and fantastic results in preventing the replication of cancer cells. What's not to like. Just wondering whether GSK, the parent company, or Sierra will be doing the trialling. Probably no more than a technicality as the decision and spandulax, or finance will be GSK. What you would expect, in my opinion, is that the time lines can become shorter, much, much shorter hopefully. Lucky them and brilliant for us.
Sierra did not have the finance to see Mono through to commercialisation, never mind SRA 737 into trialling. Getting GSK to do a buyout leaves SRA 737 in a fantastic position to be trialled in combo in a number of indications. It's not as if a new kid on the block, it's the best, the only in its class left standing with a good tox profile. What's not to like. Just wondering whether GSK, the parent company, or Sierra will be doing the trialling. Probably no more than a technicality as the spandulax, or finance will be GSK. Lucky them and brilliant for us.
Good luck to all those recovering from serious illness, including stick monkey and Thoth. I am convinced that the tox fesult is the catalyst for successful progression as we can be confident of a low tox result in human trials in PI. Meanwhile we await GSK announcement and they must realise the enormous potential of SRA 737. The finances will be there to progress this potential blockbuster.
By the way someone asked me if breast cancer could be auto immune. Hav'nt heard it is?
Sierra had a limited % increase offer on their current SP. That's because momo was already priced and SAR 737 hardly priced in at all as thatthe potential blockbuster was hidden for a reason best known to themselves. That's my worry about ii's having a major say, the finance dealing with this type of investment is probably happy to grab a small enough increment on the price as it removes any risk and looks good to his boss and to his career path. See SOG's excellent analysis of the potential blockbusters we have and why we must not let II and the likes of ii? 's decide our faith. Remember the Sierra holders were not even consulted about the sale and were totally disinfranchised.
One other aspect to be looking out for. I expect to see very, apparently reasonable posters coming on arguing that we should be content with a limited appreciation of our current SP in a To situation. Most likely they will be paid wombles and should be dispatched back to the common on the 1st available chuchooo.
Would imagine some red faces belonging to the CEO's of other major pharma companies when those with drugs that can synergise with chk1 realise the have been left holding, well nothing. Could make them even more eager to pursue the Tyk2 molecules that are well, 100% SAR.